[{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Prestige BioPharma Pte Ltd \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Epirubicin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.

                          Brand Name : Tuznue

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 31, 2024

                          Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.

                          Brand Name : Troika

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 14, 2022

                          Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank